Advertisement

Fabry Disease pp 417-432 | Cite as

Analyses of Agalsidase Alfa and Agalsidase Beta for the Treatment of Fabry Disease

  • T. Andrew Burrow
  • Gregory A. GrabowskiEmail author
Chapter

Abstract

Within the past decade, two recombinant α-galactosidase A replacement products have been developed for Fabry disease treatment: Agalsidase alfa (Replagal®, Shire TKT Pharmaceuticals, Cambridge, MA, USA) and agalsidase beta (Fabrazyme®, Genzyme Corp., Cambridge, MA, USA). Agalsidase alfa and beta are licensed in Europe, Canada, Australia, and the countries of the Pacific Rim (including Japan) at doses of 0.2 and 1.0 mg/kg body weight, respectively, whereas only agalsidase beta is licensed in the United States. The biological and therapeutic equivalency of these two recombinant alfa-galactosidase A preparations has been the subject of debate. The purpose of this chapter is to compare the available efficacy and safety data on agalsidase alfa and beta, and to provide suggestions for future comparative studies.

Keywords

Comparison Agalsidase alfa Agalsidase beta Recombinant alfa-galactosidase A Enzyme replacement therapy 

References

  1. 1.
    Enzyme Replacement Therapy with Replagal [Internet]. Shire human genetic therapies (updated April 29, 2009). Available from http://www.replagal.com/hcp_replagal.aspx. Accessed 3 Sept 2009
  2. 2.
    Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al (2001 Mar) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68(3):711–722PubMedCrossRefGoogle Scholar
  3. 3.
    Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J et al (2003 Apr) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13(4):305–313PubMedCrossRefGoogle Scholar
  4. 4.
    Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T et al (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51(3):180–188PubMedCrossRefGoogle Scholar
  5. 5.
    Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM (1996 Apr 15) Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 237(2):344–349PubMedCrossRefGoogle Scholar
  6. 6.
    Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26(7):617–627PubMedCrossRefGoogle Scholar
  7. 7.
    Beck M (2009 Feb) Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 9(2):255–261PubMedCrossRefGoogle Scholar
  8. 8.
    Clarke JT, West ML, Bultas J, Schiffmann R (2007 Aug) The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 9(8):504–509PubMedCrossRefGoogle Scholar
  9. 9.
    Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001 Jul 5) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16PubMedCrossRefGoogle Scholar
  10. 10.
    Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL et al (2006 Sep) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118(3):924–932PubMedCrossRefGoogle Scholar
  11. 11.
    Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T et al (2001 Jun 6) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 285(21):2743–2749CrossRefGoogle Scholar
  12. 12.
    Hopkin RJ, Bissler J, Grabowski GA (2003) Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease. Genet Med 5(3):144–153PubMedCrossRefGoogle Scholar
  13. 13.
    Ries M, Kim HJ, Zalewski CK, Mastroianni MA, Moore DF, Brady RO et al (2007 Jan) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130(Pt 1):143–150PubMedGoogle Scholar
  14. 14.
    Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ et al (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2(7):e598PubMedCrossRefGoogle Scholar
  15. 15.
    Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA et al (2007 Jan) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96(1):122–127PubMedCrossRefGoogle Scholar
  16. 16.
    Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ et al (2007 May) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547–1557PubMedCrossRefGoogle Scholar
  17. 17.
    Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23(6):535–542PubMedCrossRefGoogle Scholar
  18. 18.
    Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152(4). 563–570, 570.e1Google Scholar
  19. 19.
    Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y et al (2003 Dec) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28(6):703–710PubMedCrossRefGoogle Scholar
  20. 20.
    Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J et al (2008 Feb) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153–158PubMedCrossRefGoogle Scholar
  21. 21.
    Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E et al (2009) Effects of enzyme replacement therapy in patients with Anderson-Fabry disease: a prospective long term cardiac magnetic resonance imaging study. Heart 95(13):1103–1107PubMedCrossRefGoogle Scholar
  22. 22.
    Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al (2003 Sep 16) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108(11):1299–1301PubMedCrossRefGoogle Scholar
  23. 23.
    Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007 Jan 16) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86PubMedGoogle Scholar
  24. 24.
    Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006 Feb) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21(2):345–354PubMedCrossRefGoogle Scholar
  25. 25.
    Beck M (2002 Jun) Agalsidase alfa–a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 11(6):851–858PubMedCrossRefGoogle Scholar
  26. 26.
    Pastores GM, Thadhani R (2001 Aug 25) Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 358(9282):601–603PubMedCrossRefGoogle Scholar
  27. 27.
    Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004 Oct) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589–1595PubMedCrossRefGoogle Scholar
  28. 28.
    Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B et al (2008 Jul) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94(3):319–325PubMedCrossRefGoogle Scholar
  29. 29.
    Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A (2009 Apr) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11(4):256–264PubMedCrossRefGoogle Scholar
  30. 30.
    Beck M (2006 Apr) The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 95(451):43–46PubMedCrossRefGoogle Scholar
  31. 31.
    Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J et al (2009 Feb) Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 11(2):92–100PubMedCrossRefGoogle Scholar
  32. 32.
    Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A et al (2005 Feb) Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7(2):105–110PubMedCrossRefGoogle Scholar
  33. 33.
    Isman F, Hobert JA, Thompson JN, Natowicz MR (2008 Jan) Plasma chitotriosidase in lysosomal storage diseases. Clin Chim Acta 387(1–2):165–167PubMedCrossRefGoogle Scholar
  34. 34.
    Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M et al (2000 Jan 4) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97(1):365–370PubMedCrossRefGoogle Scholar
  35. 35.
    Tondel C, Bostad L, Hirth A, Svarstad E (2008 May) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51(5):767–776PubMedCrossRefGoogle Scholar
  36. 36.
    Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E et al (2008 Jun) Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 31(3):432–441PubMedCrossRefGoogle Scholar
  37. 37.
    Kovacevic-Preradovic T, Zuber M, Jost CH, Widmer U, Seifert B, Schulthess G et al (2008 Nov) Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 9(6):729–735PubMedCrossRefGoogle Scholar
  38. 38.
    Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C et al (2004 Dec) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34(12):838–844PubMedCrossRefGoogle Scholar
  39. 39.
    Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006 Apr) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69(7):1216–1221PubMedCrossRefGoogle Scholar
  40. 40.
    Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M (2009) Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 29(5):353–361PubMedCrossRefGoogle Scholar
  41. 41.
    Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G (2006 Aug) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66(2):77–84PubMedGoogle Scholar
  42. 42.
    Marinides GN (1993) Progression of chronic renal disease and diabetic nephropathy: a review of clinical studies and current therapy. J Med 24(4–5):266–288PubMedGoogle Scholar
  43. 43.
    Banikazemi M, Ullman T, Desnick RJ (2005 Aug) Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85(4):255–259PubMedCrossRefGoogle Scholar
  44. 44.
    Dehout F, Roland D, Treille de Granseigne S, Guillaume B, Van Maldergem L (2004) Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J Inherit Metab Dis 27(4):499–505PubMedCrossRefGoogle Scholar
  45. 45.
    Hoffmann B, Schwarz M, Mehta A, Keshav S (2007 Dec) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5(12):1447–1453PubMedCrossRefGoogle Scholar
  46. 46.
    Hoffmann B, Keshav S (2007 Apr) Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 96(455):84–86PubMedCrossRefGoogle Scholar
  47. 47.
    Jardim L, Vedolin L, Schwartz IV, Burin MG, Cecchin C, Kalakun L et al (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27(2):229–240PubMedCrossRefGoogle Scholar
  48. 48.
    Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002 Jun) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 18(2):4CrossRefGoogle Scholar
  49. 49.
    Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T et al (2002 Feb) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33(2):525–531PubMedCrossRefGoogle Scholar
  50. 50.
    Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42(3):247–252PubMedCrossRefGoogle Scholar
  51. 51.
    Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002 Dec) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19(6):575–586PubMedCrossRefGoogle Scholar
  52. 52.
    Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M (2004 Apr 13) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62(7):1066–1072PubMedCrossRefGoogle Scholar
  53. 53.
    Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA (2007 Dec) Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 19(6):628–635PubMedCrossRefGoogle Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  1. 1.Division of Human GeneticsCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  2. 2.Department of PediatricsUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations